Recombinant Antibody Production
Recombinant Antibody Production - Related Videos
03:22
Production and Purification of Recombinant Antibodies from Mammalian Cells
0 Views •
2025
The video explains the process of producing antibodies in mammalian host cells, from gene expression to secretion. It involves transcription, translation, signal recognition, correct folding, and eventual release into the extracellular medium via secretory vesicles.
03:38
A Method to Produce Recombinant Antibodies Against Metallopeptidase
0 Views •
2025
This video demonstrates a procedure for the production of recombinant antibodies against metallopeptidase. Recombinant plasmids carrying genes for the antibody, green fluorescent protein, and antibiotic resistance are transfected into epithelial cells with lipofectamine. The transfected cells are selected and cultivated to generate recombinant antibodies.
09:19
Recombinant Retroviral Production and Infection of B Cells
0 Views •
Cited by 2 •
2011
An efficient system of structure and function analysis of a gene in an ex vivo culture of splenic B-lymphocytes is described. This method takes advantage of recombinant retroviral production in a helper free, ecotrophic packaging cell line. Stable, heritable expression of a gene of interest within primary lymphocytes is achieved leading to generation of surface antibodies on B cells undergoing class switch recombination.
12:55
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
0 Views •
Cited by 33 •
2015
A method is described with visual accompaniment for conducting scalable, high throughput selections from phage-displayed combinatorial synthetic antibody libraries against hundreds of antigens simultaneously. Using this parallel approach, we have isolated antibody fragments that exhibit high affinity and specificity for diverse antigens that are functional in standard immunoassays.
04:12
Production and Purification of Recombinant Hepatitis B Virus Particles
0 Views •
2026
Source: Nishitsuji, H., et al. Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle. J. Vis. Exp. (2017)This video demonstrates the production and purification of recombinant Hepatitis B virus particles, enabling safe, replication-deficient viral preparations for studying early infection events and for high-throughput antiviral drug screening applications.
FAQs
Heavy- and light-chain sequences must be paired correctly because the host cell uses both antibody components to assemble the immunoglobulin. Researchers can isolate existing sequences or design them, then use the resulting construct to pursue selected specificity or affinity characteristics. This genetic control makes antibody properties adjustable rather than dependent only on the original immune-cell source.
Expression vectors connect the selected antibody genes to a format that can be introduced into host cells. Once inside, the host supplies the cellular machinery needed to assemble and secrete the antibody, after which the product can be purified. This separation between encoded instructions and cellular production enables the same construct to support consistent antibody generation.
Compared with antibodies obtained directly from immune cells, recombinant products are tied to defined cloned sequences. That traceable genetic basis supports reproducible manufacturing and allows researchers to alter affinity or specificity in a controlled way. The approach is therefore useful when experiments require consistent binding behavior and a precisely characterized antibody reagent.
A typical workflow begins by isolating or designing heavy- and light-chain genes, inserting them into expression vectors, and introducing the constructs into a host-cell system. The cells then assemble and secrete the antibody, which researchers obtain through purification. Linking these stages to cloned sequences connects the final preparation with its intended antibody design.
In infection research, recombinant antibodies can support pathogen detection and antigen characterization. Their defined sequences provide controlled molecular reagents for developing diagnostic assays and improving reproducibility across experiments. These applications help investigators distinguish infectious targets and examine their antigenic properties using antibodies whose composition and intended binding characteristics are known.
Recombinant antibody production is valuable when emerging infectious agents require rapidly adaptable reagents. Researchers can modify or redesign cloned antibody sequences to pursue altered affinity or specificity, then express updated constructs in host cells. The same strategy contributes to therapeutic design, where controlled antibody properties can support the development of candidate treatments.